You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The PCR-based tests, which detect regions in the virus' nucleocapsid gene, may only be performed at their developers' CLIA-certified labs.
The first year's pilot phase aimed to develop an infectious disease digital health and precision medicine platform connecting healthcare facilities to NYSDOH.
he firm will use the proceeds to expand manufacturing capacity for its existing and in-development COVID-19 assays.
The technologies, called non-extensible oligonucleotides and linear DNA assembly, may help the sample prep firm improve existing products.
The company, along with Softbank Investment Advisers, is offering a total of 11.5 million shares of its common stock at $84 per share.
Sienna said that Unilabs, a commercial lab in Sweden, is evaluating its hTERT bladder cancer test for routine use.
In its complaint, the Maryland-based company claimed that Natera infringes two of its patents, both titled "Methods for detection of genetic disorders."
The company plans to use the funds for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility.
The companies will use Coca-Cola bottle preforms— small plastic tubes that are heated and blown into a bottle shape for beverages — as test tubes.
The test measures a set of three host-response proteins to help distinguish between bacterial and viral infections and guide use of antibiotics.
The company already offers an antibody test, Anti-SARS-CoV-2 Rapid Test, that it is distributing for its Chinese joint venture partner Autobio Diagnostics.
Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased.
Sema4 said it will provide SARS-CoV-2 viral and antibody testing to Connecticut residents including state employees and first responders.
The company said it has production capacity for more than 50 million tests per month and that its high-throughput analyzers can deliver up to 440 tests per hour.
The lateral flow assay is designed to detect and differentiate immunoglobulin G and immunoglobulin M antibodies against SARS-CoV-2.
The template describes the data and information that should be submitted for EUA of collection kits or tests with a home self-collection component.
The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.
The deal will join Tangen's GeneSpark point-of-care instrument with LabWare's portable disease surveillance kit for SARS-CoV-2.
The company said that a large portion of the offering's proceeds would be used to end criminal and civil investigations over its past billing practices.
The test uses a proprietary at-home PCR nasal swab test with a turnaround time of 24 hours and is authorized for use by at-risk people.
UrSure is developing and commercializing products that measure adherence to HIV medications, including pre-exposure prophylaxis, or PrEP.
News items for the in vitro diagnostics industry for the week of May 25, 2020.
The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms
The company said that by the end of June it would have made available more than 500,000 kits, which allow individuals to self-collect nasal samples at home.
More than 70 percent of labs surveyed experienced supply chain interruptions, forcing them to validate three or more diagnostic testing methods.